The Company announces that it has granted the following share options (the “Options”) to Tim Mitchell, Chief Executive Officer and John Reader, Chief Scientific Officer (together, the “Directors”);

	Number of options
Tim Mitchell	2,566,666
John Reader	2,566,666

The Options have been granted with an exercise price of 1.2 pence and are exercisable until 13 March 2022.

Of the Options granted to each Director, 1,283,333 options will vest immediately, with the remaining 1,283,333 options vesting subject to pre-determined performance criteria.

In addition to the Options being granted, the Directors currently each hold options over 12,553,846 shares, which were granted on 13 December 2010 and 4 December 2009.

The Company also announces that Tim Mitchell has transferred 10,000,000 ordinary shares in the capital of the Company to his wife.

Enquires:

Sareum Holdings plc
Tim Mitchell, Chief Executive Officer	01223 497 700
Merchant Securities Limited (NOMAD)
Simon Clements	020 7628 2200
Hybridan LLP (Broker)
Claire Noyce / Deepak Reddy	020 7947 4350
The Communications Portfolio (Media enquiries)
Ariane Comstive / Caolan Mahon ariane.comstive@communications-portfolio.co.uk	020 7536 2028 / 2029

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum's Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR. For further information, please visit www.sareum.co.uk